Valuation: Resverlogix Corp.

Market Cap 19.58M 13.92M 12.4M 11.48M 10.39M 1.31B 19.81M 138M 54.03M 690M 52.22M 51.13M 2.2B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 105M 74.91M 66.75M 61.8M 55.93M 7.07B 107M 741M 291M 3.72B 281M 275M 11.84B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 week-5.88%
Current month-11.11%
1 month-11.11%
3 months-20.00%
6 months-23.81%
Current year-20.00%
1 week 0.08
Extreme 0.08
0.08
1 month 0.08
Extreme 0.08
0.12
Current year 0.08
Extreme 0.08
0.14
1 year 0.08
Extreme 0.08
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Option

Chief Financial Officer

350,000 0.1018%
7/6/26 Option

Chief Financial Officer

-350,000 0.1018%
7/6/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.88%-23.81%+14.29% 19.61M
-0.21%-4.43%+44.40%+74.13% 66.34B
+0.82%+5.41%+8.05%+73.53% 54.82B
-0.22%+6.53%+11.68%+87.32% 52.92B
+3.28%+5.58%+26.51%+50.05% 44.09B
+0.51%+9.95%+22.40%+133.92% 43.72B
-1.15%+0.39%+263.21%+594.60% 42.13B
+0.10%+9.90%+16.11%+59.33% 33.96B
-3.72%-2.38%+32.55%+2.88% 26.17B
+0.69%+5.60%+36.60%+26.94% 23.37B
Average -0.01%+3.68%+43.77%+111.70% 38.75B
Weighted average by Cap. +0.14%+4.54%+50.31%+127.48%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.43M -4.84M -4.48M -4.05M -512M -7.73M -53.69M -21.07M -269M -20.36M -19.94M -858M -7.77M -5.52M -4.92M -4.56M -4.12M -521M -7.86M -54.62M -21.43M -274M -20.71M -20.28M -873M
Net Debt 81.87M 58.2M 51.87M 48.02M 43.46M 5.49B 82.84M 576M 226M 2.89B 218M 214M 9.2B 85.79M 60.99M 54.35M 50.32M 45.54M 5.76B 86.81M 603M 237M 3.03B 229M 224M 9.64B
Projected Income Statement - Annual - Resverlogix Corp.
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-10-21 $0.0800 0.00% 48,000
26-10-20 $0.0800 -5.88% 5,000
26-10-19 $0.0850 +6.25% 3,000
26-10-16 $0.0800 -5.88% 63,264
26-10-15 $0.0850 0.00% 3,000